Evidence map›Paper›PMID 42200449›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Differences in amyloid PET positivity based on ethnoracial group and social determinants of health: The new IDEAS study.

Corey J Bolton, Peggye Dilworth-Anderson, Jon Steingrimsson, Maryanne Thangarajah, Lucy Hanna, Constantine Gatsonis, Charles Windon, Maria C Carrillo, Emily Glavin, Ilana Gareen and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Corey J BoltonDepartment of Medicine, Division of Geriatric Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Peggye Dilworth-AndersonVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jon SteingrimssonDepartment of Biostatistics, Brown University, Providence, Rhode Island, USA.
Maryanne ThangarajahCenter for Biostatistics and Health Data Science, Brown University School of Public Health, Providence, Rhode Island, USA.
Lucy HannaCenter for Biostatistics and Health Data Science, Brown University School of Public Health, Providence, Rhode Island, USA.
Constantine GatsonisDepartment of Biostatistics, Brown University, Providence, Rhode Island, USA.
Charles WindonDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.
Maria C CarrilloAlzheimer's Association, Chicago, Illinois, USA.
Emily GlavinCenter for Research and Innovation, American College of Radiology, Reston, Virginia, USA.
Ilana GareenCenter for Biostatistics and Health Data Science, Brown University School of Public Health, Providence, Rhode Island, USA.
Margo B HestonDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.
Bruce E HillnerDepartment of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Andrew MarchCenter for Research and Innovation, American College of Radiology, Reston, Virginia, USA.
Robert A RissmanDepartment of Physiology and Neuroscience, Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, California, USA.
Barry A SiegelEdward Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Karen SmithDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.
Rachel A WhitmerDivision of Research, Kaiser Permanente, Oakland, California, USA.
Christopher J WeberAlzheimer's Association, Chicago, Illinois, USA.
Gil D RabinoviciDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.
Consuelo H WilkinsDepartment of Medicine, Division of Geriatric Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-8043-513X

Funding

Catalyzing and Harmonizing Operational Innovation for Recruitment (CHOIR)U24TR004432 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, CONSUELO HOPKINS WILKINS · 2023 to 2026
$20.9M
Vanderbilt Alzheimer's Disease Research Center: REC CoreP30AG086403 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ANGELA L. JEFFERSON · 2025 to 2026
$15.0M
Reimagining Precision Medicine Approaches to AD DiagnosisR35AG072362 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI POSSIN, KATHERINE LAUREL, RABINOVICI, GIL DAN · 2021 to 2025
$4.8M
Examining the influence of sociodemographic and medical factors on plasma p-tau217 performance in diverse communitiesK23AG084850 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Corey Bolton · 2024 to 2026
$553k
Amyloid PET and Blood-Based Biomarkers of AD among Diverse PopulationsK23AG093166 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Charles Christian Windon · 2025 to 2026
$328k
The Disadvantage Exposome as a Driver of Alzheimer’s Disease PathologyK00AG097172 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Margo Heston · 2025 to 2026
$169k
Alzheimer's AssociationAmerican College of RadiologyEli Lilly and CompanyGeneral Electric HealthcareLife Molecular ImagingNCATS NIH HHS U24 TR004432NIA NIH HHS K00 AG097172NIA NIH HHS K23 AG084850NIA NIH HHS K23 AG093166NIA NIH HHS P30 AG086403NIA NIH HHS R35 AG072362NIH HHS K00AG097172NIH HHS K23AG084850NIH HHS K23AG093166NIH HHS P30AG086403NIH HHS R35 AG072362NIH HHS U24 TR004432
6 · The paper itself

Abstract

introductionThis study leverages a large, diverse cohort to characterize ethnoracial differences in amyloid positron emission tomography (PET) positivity and identify social determinants of health (SDOHs) contributing to these differences.

methodsWe assessed differences in amyloid PET positivity by ethnoracial group (Black, Latinx, or all other races/ethnicities [AORE]) among Medicare beneficiaries with cognitive impairment. Secondary analyses associated various SDOHs with amyloid PET positivity.

resultsAmong 5757 participants (21.7% Black, 20.3% Latinx, 58.1% AORE), we found lower odds of amyloid positivity in Black (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.62-0.83) and Latinx (OR: 0.78, 95% CI: 0.67-0.91) compared to AORE. Individuals in the comfortable (OR: 1.22, 95% CI: 1.05-1.42) and distressed (OR: 1.40, 95% CI: 1.08-1.82) Area Deprivation Index (ADI) groups had greater odds of amyloid positivity than individuals in the prosperous group. DISCUSSION: Amyloid PET positivity rates were lower among Black and Latinx individuals and higher among individuals in more deprived ADI categories. This has potential implications for anti-amyloid therapies.

Indexed as

AmyloidCognitive DysfunctionPositron-Emission TomographySocial Determinants of HealthAgedAged, 80 and overBlack or African AmericanFemaleHispanic or LatinoHumansMaleMedicareSocioeconomic Disparities in HealthUnited StatesAmyloidAlzheimer'samyloid PETdisparitiesethnoracial differences

Identifiers

PMID42200449
PMCPMC13240095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.